申请人:Diatide, Inc.
公开号:US06007792A1
公开(公告)日:1999-12-28
This invention relates to radiotherapeutic reagents and peptides, radiodiagnostic reagents and peptides, and methods for producing labeled radiodiagnostic and radiotherapeutic agents. Specifically, the invention relates to vasoactive intestinal peptide receptor binding peptides, derivatives and analogues of vasoactive intestinal peptide, and embodiments of such peptides radiolabeled with a radioisotope, as well as methods and kits for making, radiolabeling and using such peptides for radiodiagnostic and radiotherapeutic purposes. The invention specifically relates to vasoactive intestinal peptide receptor binding peptide derivatives and analogues of vasoactive intestinal peptide radiolabeled with technetium-99m and uses thereof as scintigraphic imaging agents. The invention also specifically relates to vasoactive intestinal peptide receptor binding peptide derivatives and analogues of vasoactive intestinal peptide radiolabeled with cytotoxic radioisotopes such as rhenium-186 (.sup.186 Re) and rhenium-188 (.sup.188 Re) for use as radiotherapeutic agents. Methods and kits for making, radiolabeling and using such peptides diagnostically and therapeutically in a mammalian body are also provided.
这项发明涉及放射治疗试剂和肽,放射诊断试剂和肽,以及制备标记的放射诊断和放射治疗剂的方法。具体而言,该发明涉及与肠道血管活性肽受体结合的肽,肠道血管活性肽的衍生物和类似物,以及用放射性同位素标记的这些肽的实施例,以及用于制备、标记和使用这些肽进行放射诊断和放射治疗目的的方法和试剂盒。该发明具体涉及与钼-99m标记的肠道血管活性肽受体结合肽衍生物和肠道血管活性肽的类似物,以及将其用作闪烁显像剂的用途。该发明还具体涉及与放射性同位素(如铼-186(^186Re)和铼-188(^188Re))标记的肠道血管活性肽受体结合肽衍生物和肠道血管活性肽的类似物,用作放射治疗剂的用途。还提供了在哺乳动物体内诊断和治疗地制备、标记和使用这些肽的方法和试剂盒。